RCKT · Rocket Pharmaceuticals, Inc.

Track RCKT — free

$3.76 +0.03 (+0.80%)

Russell 2000 member Rebalance outlook locked

Market Cap

$409.46M

109.77M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$17.25M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$283.75M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.1%

Year over year · more shares

Price change (1Y)

+13.7%

Trailing year

Short interest

13.1%

Latest settlement · 8.6 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg +6%

above

RSI (14) 56

neutral

MACD trend Positive

52-week position 42%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return +8%

trailing

6-month return −25%

trailing

YTD return +6%

this year

Relative strength −37%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $4 › 200d $4 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +23 funds added

Insider flow Distributing

Net -$176.0K over 90 days · 100% sells

Short interest Falling

13.11% of float · ▼ -7.1% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

186 holders — mid 3-yr range

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

EPS growth +26%

Y/Y

Free cash flow $-190.5M

Quant / Vol

risk profile

Very High

Volatility 71%

annualized · 1-yr

Max drawdown −51%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

+6% Bullish

RSI (14)

56 Neutral

MACD trend

Positive Bullish

52-week position

42% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $4 › 200d $4 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +23 funds added

Insider flow Distributing

Net -$176.0K over 90 days · 100% sells

Short interest Falling

13.11% of float · ▼ -7.1% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

186 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $3 Now $4 · 42% Range high $5

vs 200-day avg +5% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RCKT Rocket Pharmaceuticals, Inc. this stock	$409.46M	+6.3%	—	—	13.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+20.8%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.82B	+6.7%	+20.8%	20.4	2.3%
ARGX Argenx SE	$64.16B	+22.3%	—	—	1.9%
MRNA Moderna, Inc.	$61.59B	+423.1%	+4.3%	—	13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

186

% held: 92.7%
Net QoQ: +4.1M sh
Top holder: RTW INVESTMENTS, LP

Held Float

View

Held by Funds

Fund positions

169

View

Short & Settlement

Short Interest Falling

Shares short

14.4M

Days to cover: 8.6d
Change: -1.1M sh

View

Short Volume

Short vol %

51%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

322

Value: $1.1K
As of: Aug 4, 2026

View

Off-Exchange

Off-exchange %

47.4%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$176.0K

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-223.1M
EPS diluted: $-2.01

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 27, 2026
This year: 18

View

Proposed Sales

Value

$7.8K

Shares: 2.3K
Filed: Aug 18, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
RCKT	-1.3%	+8.4%	-24.8%	+0.3%	+6.3%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-0.8%	+9.7%	-37.4%	+1.0%	-5.4%

Key facts CIK 1281895 CUSIP 77313F106 13F (30d) 156 filings 155 filers Visit website Investor relations

RCKT · Rocket Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance